Here’s one to avoid – Oramed Pharmaceuticals Print E-mail
By Brian Wilson-Lead Contributor   
Tuesday, 11 February 2014 12:50
Oramed (ORMP) is another diabetes company that is looking to enter the insulin market. This time, the twist is that the insulin comes in an oral form (a capsule) with special proteins that allow for proper absorption.
Read more...
 
This Biotech Is Flying Under The Radar With Catalyst Upcoming Print E-mail
By Scott Matusow   
Tuesday, 11 February 2014 09:54
Today we are going to take a look at a developmental biotech which well-known biotech institutional investor firm Baker Brothers LLC has a substantial position in.
Read more...
 
Why La Jolla Pharma has very favorable Risk/Reward Print E-mail
By Brian Wilson - Lead Contributor   
Tuesday, 04 February 2014 10:01
It's becoming more and more difficult to find biotechnology stocks that are attractively valued these days. The NASDAQ Biotechnology index (NBI), the best "barometer" for this sector, is up 253% in the last 5 years.
Read more...
 
A Top-Down View on Multibillion Dollar Colorectal Cancer Diagnostics Market Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 27 January 2014 00:13
Routine colorectal cancer screening is something that tens of millions in the United States go through every few years.
Read more...
 
ThermoGenesis Merging with TotiRx – Heating Up Cell Therapy M&A Print E-mail
By Brian Wilson-Lead Contributor   
Tuesday, 21 January 2014 02:01
In a previous article, I mentioned that stem cell companies are coming back in a big way.
Read more...
 
Near-Term Catalysts Should Rally These Biotechs Print E-mail
By Scott Matusow   
Friday, 10 January 2014 09:41
Today, we will list five biopharmaceutical companies with upcoming catalysts. We expect these company's stock prices to appreciate significantly in the short term as they draw closer to their respective catalysts.
Read more...
 
Bullish on Progenics Pharma With 2 Near-Term Catalysts Print E-mail
By Scott Matusow   
Tuesday, 07 January 2014 12:31
Catalyst events for developmental pharmas usually mean the associated stock prices see good appreciation in the period leading up to these events.
Read more...
 
Neostem Might Double on Phase II Results Print E-mail
By Mary Davila   
Monday, 06 January 2014 08:50
In the last Neostem article we discussed some of the key events coming in 2014 that could significantly impact the share price, and we provided some superficial details on the company's structure and financial situation.
Read more...
 
Small Cap BioPharmas With Near Term Catalysts Print E-mail
By Scott Matusow   
Friday, 03 January 2014 11:22
In the small cap biopharma segment of the market that we follow daily at stockmatusow, stock prices sometimes experience volatile moves, especially as a near-term catalyst event approaches.
Read more...
 
Synergy Pharma Seeks To Treat Gastral Disorders And Diseases Print E-mail
By Scott Matusow   
Thursday, 02 January 2014 09:43
Today at stockmatusow, we focus on a Bio-Pharmaceutical company with several near-term catalysts and give our thesis why we believe the company makes for a good long term speculative investment.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 15 of 56

Newsletter